Matthew Jarpe

Matthew Jarpe is an accomplished biochemist and biopharmaceutical professional with extensive experience in drug development and innovation. Currently serving as a Scientific Advisory Board Member at Sensorium Therapeutics since November 2022, Matthew previously founded Rizana Therapeutics in October 2020, focusing on novel treatments for addiction. As Vice President of Target Biology at Korro Bio, Inc. from June 2019 to October 2020, Matthew contributed to pioneering mRNA editing technologies. Matthew co-founded Regenacy Pharmaceuticals LLC, where, as Vice President of Research and Development from December 2016 to May 2020, innovative protein function regeneration treatments utilizing isoform selective HDAC inhibitors were developed. Additionally, Matthew held significant roles at Acetylon Pharmaceuticals, Surface Logix, Biogen Idec, and the National Jewish Medical Research Center, contributing to advancements in drug candidates and therapeutic strategies throughout a career that began after earning a PhD in Biochemistry from The Johns Hopkins University School of Medicine and a BS in Biology from the New Mexico Institute of Mining and Technology.